Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Artery Diseases | 7 | 2020 | 100 | 1.800 |
Why?
|
| Dyslipidemias | 4 | 2017 | 108 | 1.540 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 96 | 1.400 |
Why?
|
| Lipids | 4 | 2014 | 278 | 1.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 394 | 1.240 |
Why?
|
| Atherosclerosis | 5 | 2016 | 256 | 0.960 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 375 | 0.910 |
Why?
|
| Carotid Arteries | 4 | 2018 | 131 | 0.910 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2020 | 39 | 0.710 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2018 | 58 | 0.610 |
Why?
|
| HIV Infections | 2 | 2020 | 961 | 0.600 |
Why?
|
| Cause of Death | 1 | 2020 | 273 | 0.580 |
Why?
|
| Heart Sounds | 2 | 2025 | 2 | 0.580 |
Why?
|
| American Heart Association | 1 | 2017 | 106 | 0.500 |
Why?
|
| Primary Prevention | 1 | 2017 | 85 | 0.500 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 188 | 0.480 |
Why?
|
| Cyclin D1 | 1 | 2016 | 85 | 0.470 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 156 | 0.460 |
Why?
|
| Guideline Adherence | 1 | 2017 | 236 | 0.460 |
Why?
|
| Pericardium | 1 | 2016 | 72 | 0.460 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 23 | 0.440 |
Why?
|
| Anticholesteremic Agents | 2 | 2016 | 154 | 0.440 |
Why?
|
| Carotid Stenosis | 2 | 2012 | 114 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 3476 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1338 | 0.410 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 754 | 0.400 |
Why?
|
| Adipose Tissue | 1 | 2016 | 270 | 0.400 |
Why?
|
| Azetidines | 2 | 2016 | 36 | 0.390 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 190 | 0.390 |
Why?
|
| Thrombosis | 2 | 2015 | 309 | 0.390 |
Why?
|
| Heart Diseases | 1 | 2015 | 257 | 0.380 |
Why?
|
| Heart Ventricles | 1 | 2017 | 650 | 0.380 |
Why?
|
| Coronary Stenosis | 1 | 2012 | 31 | 0.370 |
Why?
|
| Jejunum | 1 | 2012 | 76 | 0.360 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 125 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 624 | 0.360 |
Why?
|
| Hypertension | 1 | 2017 | 757 | 0.340 |
Why?
|
| MicroRNAs | 1 | 2016 | 580 | 0.340 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 173 | 0.330 |
Why?
|
| Disease Progression | 4 | 2020 | 1531 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1053 | 0.320 |
Why?
|
| Cholesterol, LDL | 6 | 2018 | 246 | 0.280 |
Why?
|
| Blood Glucose | 1 | 2012 | 867 | 0.280 |
Why?
|
| Middle Aged | 14 | 2020 | 27573 | 0.260 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2006 | 4 | 0.250 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 8 | 0.250 |
Why?
|
| Humans | 25 | 2025 | 93515 | 0.250 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 91 | 0.240 |
Why?
|
| Heart Auscultation | 1 | 2025 | 3 | 0.230 |
Why?
|
| Male | 16 | 2025 | 44557 | 0.220 |
Why?
|
| Niacin | 4 | 2016 | 37 | 0.200 |
Why?
|
| Cardiology | 1 | 2025 | 120 | 0.200 |
Why?
|
| Risk Factors | 4 | 2020 | 5899 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2018 | 9099 | 0.190 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 269 | 0.180 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 356 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3830 | 0.180 |
Why?
|
| Biomarkers | 4 | 2018 | 1910 | 0.170 |
Why?
|
| Incidence | 3 | 2015 | 1701 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2006 | 811 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1741 | 0.160 |
Why?
|
| Time Factors | 4 | 2018 | 5410 | 0.160 |
Why?
|
| Students, Medical | 1 | 2025 | 435 | 0.150 |
Why?
|
| Female | 12 | 2025 | 48702 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2025 | 822 | 0.150 |
Why?
|
| Coronary Angiography | 2 | 2012 | 231 | 0.140 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 28 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 889 | 0.130 |
Why?
|
| Compliance | 1 | 2017 | 16 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 887 | 0.130 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 43 | 0.130 |
Why?
|
| Chest Pain | 1 | 2017 | 45 | 0.130 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 14 | 0.120 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 28 | 0.120 |
Why?
|
| Heart Failure | 1 | 2006 | 1386 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 413 | 0.120 |
Why?
|
| Melanocytes | 1 | 2016 | 60 | 0.120 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 98 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 27 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2025 | 1090 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2016 | 273 | 0.120 |
Why?
|
| Adult | 8 | 2018 | 27918 | 0.110 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 17 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 985 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1103 | 0.110 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2015 | 72 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2016 | 515 | 0.100 |
Why?
|
| Cisplatin | 1 | 2016 | 568 | 0.100 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 72 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1161 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 502 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2020 | 3054 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 304 | 0.100 |
Why?
|
| Pyrroles | 2 | 2011 | 165 | 0.100 |
Why?
|
| Apoptosis | 2 | 2016 | 1721 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2441 | 0.090 |
Why?
|
| Ezetimibe | 1 | 2012 | 37 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 759 | 0.090 |
Why?
|
| Simvastatin | 2 | 2016 | 106 | 0.090 |
Why?
|
| Melanoma | 1 | 2016 | 495 | 0.090 |
Why?
|
| Cell Line | 1 | 2016 | 2464 | 0.090 |
Why?
|
| Smoking | 1 | 2015 | 648 | 0.090 |
Why?
|
| Global Health | 1 | 2013 | 208 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2755 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1931 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1906 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2016 | 1691 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 27 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 20434 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 69 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2303 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 233 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2006 | 145 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1729 | 0.050 |
Why?
|
| United States | 1 | 2017 | 7622 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2025 | 238 | 0.050 |
Why?
|
| Animals | 3 | 2015 | 28155 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 988 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1713 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 1847 | 0.040 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 214 | 0.030 |
Why?
|
| Colestipol | 1 | 2016 | 3 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 28 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 129 | 0.030 |
Why?
|
| Hyperlipoproteinemias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 231 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 65 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 308 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 54 | 0.030 |
Why?
|
| Streptokinase | 1 | 1995 | 11 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 296 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 290 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1995 | 13 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 148 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 422 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 784 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 379 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 169 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 94 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 876 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 729 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 555 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 470 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1133 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 962 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 269 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 254 | 0.020 |
Why?
|
| Idaho | 1 | 2011 | 9 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2011 | 36 | 0.020 |
Why?
|
| Washington | 1 | 2011 | 49 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 204 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2850 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 555 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2011 | 4560 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 824 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1210 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 230 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2026 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 1001 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1395 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2007 | 11 | 0.020 |
Why?
|
| Allylamine | 1 | 2007 | 14 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7061 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1176 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2465 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3502 | 0.010 |
Why?
|
| Brain | 1 | 2015 | 2391 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 4272 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2562 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 12269 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2715 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1995 | 297 | 0.010 |
Why?
|